Mr. Swapan Kakumanu reports

NETRAMARK REPORTS ITS ANNUAL GENERAL AND SPECIAL MEETING RESULTS

Netramark Holdings Inc.'s successful annual general and special meeting of shareholders was held on July 13, 2026. A total of 42,813,285 common shares (approximately 47.59 per cent of the outstanding common shares) were represented in person or proxy.

1. Number of directors

Resolution to set the number of directors of the company for the ensuing year at four persons was passed by 99.93 per cent for and 4.064 per cent against.

2. Election of directors

Each of the following individuals was elected as a director of the company as approved by a vote by ballot, for a term expiring at the conclusion of the next annual meeting of shareholders of the company or until his or her successor is elected or appointed, as follows.

3. Appointment of auditor

The appointment of Horizon Assurance LLP, chartered professional accountants, as the auditor of the company, to hold office until the next annual meeting of shareholders of the company and the authorization of the directors of the company to fix the auditor's remuneration were approved by a resolution passed by a vote by ballot, with 44,806,875 (99.984 per cent) total votes cast for and 6,410 (0.016 per cent) withheld.

4. Approval 2026 rolling stock option plan

Resolution to approve the 2026 rolling stock option plan passed by a vote by ballot, with 44,412,430 (99.727 per cent) total votes cast for and 121,465 (0.273 per cent) against.

5. Approval of the 2026 equity incentive plan

Resolution to approve the 2026 equity incentive plan passed by a vote by ballot, with 44,412,430 (99.727 per cent) total votes cast for and 121,465 (0.273 per cent) against.

About Netramark Holdings Inc.

Netramark is focused on being a leader in the development of generative artificial intelligence/machine learning (ML) solutions that are targeted at the biotechnology and pharmaceutical industries. The company's product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows Netramark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activate traditional AI/ML methods. The result is that Netramark can work with much smaller data sets often prevalent in clinical trials and accurately segment diseases into different types as well as help to classify patients for sensitivity to drugs and/or efficacy of treatment.

We seek Safe Harbor.